866-997-4948(US-Canada Toll Free)

Published on : Mar 19, 2015

AstraZeneca has decided that it will not go alone for marketing Movantik but will collaborate with Japanese drugmaker Daiichi Sankyo for the purpose. Daiichi Sankyo has reportedly signed a $200 million deal for helping the launch of the constipation pill. 

Daiichi Sankyo has signed the agreement for earning the co-marketing rights of the medicine of its sales in the U.S. Movantik had won approval from the FDA in the September of the year 2014. Depending on sales of the medicine, Daiichi Sankyo will also shell out another $625 million against milestone payments. 

According to the deal, AstraZeneca will be the manufacturer of the drug, it will book sales and pay part of the sales to Daiichi Sankyo along the way. Both of the companies will run their own commercial operations and field their own sales representatives. 

The companies are planning to bring the drug to the market early next month. AstraZeneca’s EVP Paul Hudson said in a statement that AstraZeneca is very delighted about the collaboration with Daiichi Sankyo. The collaboration will help AstraZeneca in expanding its commercialization of the medicine in the U.S. market so as to get the important medicine to the huge pool of patients who are suffering from opioid induced constipation. 

Movantik (naloxegol) is developed in corporation with Nektar Therapeutics, and is highly regarded as a distinctive treatment method for constipation that is induced by opioid painkillers. But the drug will also have to face a few issues - analysts say that patients as well as doctors are not very savvy about constipation that is induced from opioid. Patients prefer more the use of over-the-counter medicines for constipation than going for a prescription solution.